The Transthyretin Amyloidosis Treatment Market Overview 2025 report reveals that the market size has grown significantly over the past few years, with projections indicating further expansion.
What are the Historical Growth Trends in the Transthyretin Amyloidosis Treatment Market?
The value of the Transthyretin Amyloidosis Treatment market has shown significant growth historically. It is estimated to rise from $5.52 billion in 2024 to $5.95 billion in 2025, signifying a compound annual growth rate (CAGR) of 7.8%.
What are the 2025 Market Projections: Forecasted Size & Growth Rate for the Transthyretin Amyloidosis Treatment Industry?
The forecasted market size for the Transthyretin Amyloidosis Treatment Global Market Report 2025 is projected to reach $8.04 billion by 2029, growing at a compound annual growth rate (CAGR) of 7.8%.
Download Your Free Sample of the 2025 Transthyretin Amyloidosis Treatment Market Report and Uncover Key Trends Now!
What are the Key Growth Drivers Fueling the Transthyretin Amyloidosis Treatment Market?
The key drivers in the transthyretin amyloidosis treatment market are:
• Expanded therapeutic pipeline for the treatment of transthyretin amyloidosis
• Increased genetic screening for early diagnosis of the disease
• Global efforts towards spreading awareness of rare diseases like transthyretin amyloidosis
• Improved access to treatment and personalized medicine approaches.
Global Market Segmentation: Identifying Major Transthyretin Amyloidosis Treatment Industry Segments
The transthyretin amyloidosis treatment market covered in this report is segmented –
1) By Type: Transthyretin Amyloidosis With Polyneuropathy (ATTR-PN), Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
2) By Drug: Tafamidis, Patisiran, Inotersen, Other Drugs
3) By Therapy: Targeted Therapy, Supportive Therapy, Pipeline Therapy
4) By Distribution Channel: Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies
Pre-order the 2025 Transthyretin Amyloidosis Treatment Global Market Report for Fast Delivery & Comprehensive Insights!
What are the Emerging Trends Shaping the Future of the Transthyretin Amyloidosis Treatment Market?
The key trends in the transthyretin amyloidosis treatment market are:
• Emergence of combination therapies is a key trend shaping the future.
• Strategic partnerships for drug development are gaining traction.
• There is a growing focus on targeting peripheral and cardiac manifestations.
• Incorporation of real-world evidence in treatment guidelines is increasingly becoming the norm.
Who Are the Top Competitors & Leading Players in the Transthyretin Amyloidosis Treatment Market?
Major companies in the transthyretin amyloidosis treatment market are:
• Pfizer Inc.
• AbbVie Inc.
• Sanofi S.A.
• Bristol Myers Squibb Company
• AstraZeneca PLC
• GSK PLC
• Novo Nordisk A/S
• Merck & Co. Inc.
• Astellas Pharma Inc.
• Alexion Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• PTC Therapeutics
• Ionis Pharmaceuticals
• Prothena Corporation PLC
• BridgeBio Pharma Inc.
• Sorrento Therapeutics Inc.
• Intellia Therapeutics
• Akcea Therapeutics Inc.
• Eidos Therapeutics Inc.
• Acrotech Biopharma Inc.
• Spectrum Pharmaceuticals Inc.
• Neurimmune AG
• BELLUS Health Inc.
• Corino Therapeutics Inc.
• Celgene Corp
• SOM Innovation Biotech S.A.
Regional Dominance: Which Area Leads the Global Transthyretin Amyloidosis Treatment Market?
North America was the largest region in the transthyretin amyloidosis treatment market in 2024
